Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Nordisk Already Plans A 'Next Generation' Oral Semaglutide - CEO

Mar 08 2018

• By Sten Stovall

Anatomy — Oral Semaglutide Will Be Aimed At Diabetes, Obesity And Fatty Liver • Source: Shutterstock

Related Content

Novo Nordisk's Oral Semaglutide Succeeds In First Phase III, But Prompts Questions

Feb 23 2018

Related Companies

Novo Nordisk A/S

Eli Lilly and Company

Boehringer Ingelheim GmbH

Merck & Co., Inc.

Additional Topics

Business Strategies Companies Commercial Clinical Trials Strategy Research & Development Metabolic Disorders Cardiovascular BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.